| Literature DB >> 20953383 |
Raheleh Khorsan1, Ian D Coulter, Cindy Crawford, An-Fu Hsiao.
Abstract
A systematic review was conducted to assess the level of evidence for integrative health care research. We searched PubMed, Allied and Complementary Medicine (AMED), BIOSIS Previews, EMBASE, the entire Cochrane Library, MANTIS, Social SciSearch, SciSearch Cited Ref Sci, PsychInfo, CINAHL, and NCCAM grantee publications listings, from database inception to May 2009, as well as searches of the "gray literature." Available studies published in English language were included. Three independent reviewers rated each article and assessed the methodological quality of studies using the Scottish Intercollegiate Guidelines Network (SIGN 50). Our search yielded 11,891 total citations but 6 clinical studies, including 4 randomized, met our inclusion criteria. There are no available systematic reviews/meta-analyses published that met our inclusion criteria. The methodological quality of the included studies was assessed independently using quality checklists of the SIGN 50. Only a small number of RCTs and CCTs with a limited number of patients and lack of adequate control groups assessing integrative health care research are available. These studies provide limited evidence of effective integrative health care on some modalities. However, integrative health care regimen appears to be generally safe.Entities:
Year: 2010 PMID: 20953383 PMCID: PMC2952316 DOI: 10.1155/2011/636134
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Official keywords as entered into the databases were as follows:
| (i) (integrated or integrative) and medicine |
| (ii) (integrated or integrative) and health* |
| (iii) multidisciplinary care and alternative medicine |
| (iv) multidisciplinary care and complementary medicine |
| (v) (complementary or alternative) and conventional and (medicine or healthcare) |
| (vi) delivery of healthcare and (integrated or integrative) |
| (vii) (integrated or integrative) and patient evaluation |
| (viii) (integration and medicine) and (complementary or alternative) |
| (ix) (complementary or alternative) and medicine and (mainstream or biomedicine or orthodox). |
Figure 1Systematic review flow chart.
SIGN checklist [1].
| Section 1: Internal validity* | |
|
| |
| Item | Description |
|
| |
| 1.1 | Study addresses appropriate, clearly focused question. |
| 1.2 | Treatment group assignment is randomized. |
| 1.3 | Adequate concealment method is used. |
| 1.4 | Subjects and investigators are kept “blind” about treatment allocation. |
| 1.5 | Treatment and control groups are similar at the start of the trial. |
| 1.6 | Only difference between groups is the treatment under investigation. |
| 1.7 | Outcomes are measured in a standard, valid, and reliable way. |
| 1.8 | What percentage of subjects in each treatment arm dropped out before the study was completed (i.e., record %)? |
| 1.9 | All subjects are analyzed in the groups to which they were randomly allocated (intention to treat analysis). |
| 1.10 | If the study is multisite, results are comparable for all sites. |
|
| |
| Section 2: Overall assessment** | |
|
| |
| How well was the study done to minimize bias? How valid is the study? Code ++, +, or − | |
|
| |
| *Each item in Section 1 is to be evaluated using these criteria: | |
| (i) | Well covered |
| (ii) | Adequately addressed |
| (iii) | Poorly addressed |
| (iv) | Not addressed |
| (v) | Not reported |
| (vi) | Not applicable |
|
| |
| **The overall assessment uses the following ratings. | |
| ++ |
|
| + |
|
| − |
|
Descriptive of clinical trials of choice of care (multidimensional) integrative healthcare interventions (n = 7).
| Reference | Design | Sample | Trial duration | Intervention | Control | Primary measures | Evidence direction on primary# | SIGN score* | Adverse events score |
|---|---|---|---|---|---|---|---|---|---|
|
Krucoff et al. 2001 [ | RCT | 150 | 6 months | MANTRA | UC | DUREL, SSTA, Risk Stratification, and post-PCI ischemia | Weak | ++ | 100 |
| Gender: 1 F | |||||||||
| Mean Age: 63 | |||||||||
|
| |||||||||
|
Krucoff et al. 2005 [ | RCT | 748 | 6 months | MANTRA: MIT or MIT plus prayer | UC or Prayer | DUREL, SSTA, and mood assessed by VAS before PCI for unstable coronary syndromes | Weak | ++ | 100 |
| Gender: 214 F | |||||||||
| Mean Age: 65 | |||||||||
|
| |||||||||
|
Seskevich et al. 2004 [ | RCT | 150 | 15 months | MANTRA | UC | Mood assessed by VAS before PCI for unstable coronary syndromes | Mixed | ++ | 0 |
| Gender: 1 F | |||||||||
| Mean Age: 64 | |||||||||
|
| |||||||||
|
Edelman et al. 2006 [ | RCT | 154 | 10 months | PHP | UC | 10-year risk of CHD (FRS) | Strong | + | 0 |
| Gender: 81 F | |||||||||
| Mean Age: 53 | |||||||||
|
| |||||||||
|
Carlsson et al. 2001 [ | CCT | 120 | 1 year | ABCW | CBCW | Life satisfaction (EORTC QLQ-C30, LSQ & MAC) | Weak | NA | 100 |
| Gender: F | |||||||||
| Mean Age: 49 | |||||||||
|
| |||||||||
|
Carlsson et al. 2004 [ | CCT | 60 | 6 months plus follow-up | ABCW | CBCW | Life satisfaction (EORTC QLQ-C30 & LSQ) | Strong | NA | 100 |
| Gender: F | |||||||||
| Mean Age: 49 | |||||||||
Abbreviations: ABCW: Women with breast cancer, anthroposophic therapy; CBCW: Women with breast cancer, conventional therapy; CHC: Coronary heart disease; DUREL: Duke University religion index; EORTC QLQ-C30: European organization for research and treatment of cancer, quality of life questionnaire core 30; FRS: Framingham risk score; LSQ: Life satisfaction questionnaire; MAC: Mental adjustment to cancer scale; MANTRA: Monitoring & actualization of noetic training; MIT: Music, imagery, and touch; PCI: percutaneous coronary intervention; PHP: Personalized health planning; SMT: Spinal manipulative therapy; SSTA: Spielberger state-trait anxiety inventory; U: Unknown; UC: Usual care; and VAS: Visual analog scale.
#Evidence direction on primary measures. Weak: no outcome measures positive despite sufficient statistical power to do so, Mixed: at least one primary outcome measure positive at the level of P < .05, Strong ≥ 50% of measures positive at the level of P < .05, and Inconclusive: study failed to demonstrate a change but lacked the statistical power to demonstrate.
*SIGN checklist for RCTs and controlled clinical trials
++: Strong. All or most of the criteria have been fulfilled.
+: Article is neither exceptionally strong nor exceptionally weak.
−: Weak. Few or no criteria fulfilled.
SAS-CT Adverse Events Scoring.
| The safety assessment score for controlled clinical trials (SAS-CT) consists of six major domains. Each domain and subgroup has different weightings according to its degree of important and rate of occurrence. |
|---|
| The maximum subscores of: |
| (i) adverse events definitely not related to the intervention (AEs-NR) and adverse drug reactions (ADRs) are 27 points, |
| (ii) serious adverse events definitely not related to the intervention (SAEs-NR) and serious adverse drug reactions (SADRs) are 13.5 points, |
| (iii) drop-outs due to AE/SAEs-NR and ADRs/ SADRs have a maximum subscore of 9.5 points each. |
|
|
| Total SAS-CT score per control clinical trial equals 100 points. |
|
|
| Quality is based on the degree of the importance of the subdomains. |
|
|
| The SAS-CT is separated into three quality levels: |
| (i) poor (0 < SAS-CT < 28) |
| (ii) medium (28 < SAS-CT < 68) |
| (iii) high quality safety reporting (68 < SAS-CT < 100) |
Items on internal validity*.
| Reference | 1.1 | 1.2 | 1.3 | 1.4 | 1.5 | 1.6 | 1.7 | 1.8 | 1.9 | 1.10 |
| Study addresses appropriate, clearly focused question. | Treatment group assignment is randomized | Adequate concealment method is used. | Subjects and investigators are kept “blind” about treatment allocation. | Treatment and control groups are similar at the start of the trial. | Only difference between groups is the treatment under investigation | Outcomes are measured in a standard, valid and reliable way. | What % of subjects in each treatment arm dropped out before the study was completed | All subjects are analyzed in the groups to which they were randomly allocated (intention to treat analysis). | If the study is multi-site, results are comparable for all sites. | |
|
| ||||||||||
| Krucoff et al. 2001 [ | Well Covered | Well Covered | Well Covered | Adequately Addressed | Well Covered | Well Covered | Well Covered | (1) MANTRA = 2% | Well Covered | Not Applicable |
|
| ||||||||||
|
Krucoff et al. 2005 [ | Well Covered | Well Covered | Well Covered | Adequately Addressed | Well Covered | Well Covered | Well Covered | (1) MIT + Prayer = 2% | Well Covered | Poorly Addressed |
| (2) Prayer = 4% | ||||||||||
| (3) MIT = 6% | ||||||||||
| (4) UC = 5% | ||||||||||
|
| ||||||||||
| Seskevich et al. [ | Well Covered | Well Covered | Well Covered | Adequately Addressed | Well Covered | Well Covered | Well Covered | (1) MANTRA = 2% | Well Covered | Poorly Addressed |
|
| ||||||||||
|
Edelman et al. [ | Well Covered | Well Covered | Poorly Addressed | Poorly Addressed | Adequately Addressed | Adequately Addressed | Well Covered | (1) PHP = 27% | Well Covered | Not Applicable |
| (2) UC = 14% | ||||||||||
Abbreviations: CMA: Conventional medical analgesia; EA: Electro-acupuncture technique; PCB: Paracervical block; MIT: Music, imagery, and touch; PHP: Personalized health planning; SMT: Spinal manipulative therapy; TMS: transcranial magnetic stimulation; and UC: Usual care.
*Each item in Section 1 is to be evaluated using these criteria:
(i) well covered,
(ii) adequately addressed,
(iii) poorly addressed,
(iv) not addressed (i.e., not mentioned, or indicates that this aspect was ignored),
(v) not reported (i.e., mentioned, but insufficient detail to allow assessment),
(vi) not applicable.